Excelsior Medical Co., Ltd. (TPE:4104)
Taiwan
· Delayed Price · Currency is TWD 88.30
+0.20 (0.23%)
Apr 2, 2025, 1:35 PM CST
Excelsior Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 8,539 | 8,233 | 7,187 | 6,573 | 6,675 | Upgrade
|
| Revenue | 8,539 | 8,233 | 7,187 | 6,573 | 6,675 | Upgrade
|
| Revenue Growth (YoY) | 3.71% | 14.56% | 9.34% | -1.53% | 3.38% | Upgrade
|
| Cost of Revenue | 6,757 | 6,564 | 5,673 | 5,199 | 5,369 | Upgrade
|
| Gross Profit | 1,781 | 1,670 | 1,514 | 1,374 | 1,307 | Upgrade
|
| Selling, General & Admin | 1,032 | 973.59 | 893.28 | 770.54 | 774.52 | Upgrade
|
| Other Operating Expenses | -4.14 | -5.85 | 0.93 | 1.41 | 0.08 | Upgrade
|
| Operating Expenses | 1,028 | 966.84 | 907.43 | 779 | 777.5 | Upgrade
|
| Operating Income | 753.32 | 702.88 | 606.61 | 595.03 | 529.07 | Upgrade
|
| Interest Expense | -18.65 | -14.32 | -5.93 | -3.65 | -7.44 | Upgrade
|
| Interest & Investment Income | 93.56 | 78.85 | 44.99 | 30.01 | 46.49 | Upgrade
|
| Earnings From Equity Investments | 323.19 | 342.3 | 290.24 | 233.43 | 242.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.3 | -1.62 | 7.78 | -0.95 | 0.74 | Upgrade
|
| Other Non Operating Income (Expenses) | 14.03 | 16.26 | 21.22 | 25.14 | 18.6 | Upgrade
|
| EBT Excluding Unusual Items | 1,172 | 1,124 | 964.9 | 879.01 | 829.48 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.86 | -0.69 | -1.76 | -6.64 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.76 | 20.42 | 0.16 | -0.01 | -0.1 | Upgrade
|
| Other Unusual Items | - | - | 0.4 | 1.37 | - | Upgrade
|
| Pretax Income | 1,174 | 1,144 | 963.7 | 873.74 | 829.38 | Upgrade
|
| Income Tax Expense | 203.31 | 221.23 | 178.4 | 151.45 | 160.3 | Upgrade
|
| Earnings From Continuing Operations | 971.06 | 922.85 | 785.3 | 722.29 | 669.09 | Upgrade
|
| Minority Interest in Earnings | -199.8 | -176.25 | -117.85 | -115.14 | -97.42 | Upgrade
|
| Net Income | 771.26 | 746.61 | 667.45 | 607.15 | 571.67 | Upgrade
|
| Net Income to Common | 771.26 | 746.61 | 667.45 | 607.15 | 571.67 | Upgrade
|
| Net Income Growth | 3.30% | 11.86% | 9.93% | 6.21% | 11.06% | Upgrade
|
| Shares Outstanding (Basic) | 163 | 163 | 163 | 163 | 163 | Upgrade
|
| Shares Outstanding (Diluted) | 164 | 164 | 164 | 164 | 164 | Upgrade
|
| Shares Change (YoY) | 0.01% | -0.09% | -0.05% | 0.34% | 9.73% | Upgrade
|
| EPS (Basic) | 4.72 | 4.57 | 4.08 | 3.72 | 3.51 | Upgrade
|
| EPS (Diluted) | 4.70 | 4.55 | 4.07 | 3.69 | 3.49 | Upgrade
|
| EPS Growth | 3.30% | 11.88% | 10.16% | 5.78% | 1.25% | Upgrade
|
| Free Cash Flow | 2,357 | -19.27 | 465.53 | 780.36 | 838.72 | Upgrade
|
| Free Cash Flow Per Share | 14.37 | -0.12 | 2.83 | 4.75 | 5.12 | Upgrade
|
| Dividend Per Share | 3.800 | 3.619 | 3.311 | 3.023 | 3.023 | Upgrade
|
| Dividend Growth | 5.00% | 9.31% | 9.50% | - | 6.06% | Upgrade
|
| Gross Margin | 20.86% | 20.28% | 21.07% | 20.90% | 19.57% | Upgrade
|
| Operating Margin | 8.82% | 8.54% | 8.44% | 9.05% | 7.93% | Upgrade
|
| Profit Margin | 9.03% | 9.07% | 9.29% | 9.24% | 8.56% | Upgrade
|
| Free Cash Flow Margin | 27.60% | -0.23% | 6.48% | 11.87% | 12.56% | Upgrade
|
| EBITDA | 946.62 | 866.09 | 741.45 | 717.68 | 616.34 | Upgrade
|
| EBITDA Margin | 11.09% | 10.52% | 10.32% | 10.92% | 9.23% | Upgrade
|
| D&A For EBITDA | 193.3 | 163.21 | 134.84 | 122.65 | 87.27 | Upgrade
|
| EBIT | 753.32 | 702.88 | 606.61 | 595.03 | 529.07 | Upgrade
|
| EBIT Margin | 8.82% | 8.54% | 8.44% | 9.05% | 7.93% | Upgrade
|
| Effective Tax Rate | 17.31% | 19.34% | 18.51% | 17.33% | 19.33% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.